Key result
Leadless WiSE-CRT improves symptoms and LV remodeling in conventional CRT nonresponders or untreatable patients.
Why the study?
Leadless pacemakers and subcutaneous ICDs are increasingly used to reduce risks of transvenous systems, but the impact of leadless pacemaker positioning on S-ICD sensing in completely leadless CRT and defibrillation systems is not well defined.
May support leadless CRT in select nonresponders; leaves open need for randomized trials before practice change.
Leadless pacemakers and subcutaneous implantable cardioverter-defibrillators (S-ICDs) are attractive options to reduce the risks associated with transvenous systems, such as vascular access complications and recurrent lead infections, and their clinical use is increasing.1,2 Leadless cardiac resynchronization therapy (CRT) can be delivered using the WiSE-CRT system (EBR Systems, Sunnyvale, CA), which improves symptoms and left ventricular (LV) remodeling in patients who are untreatable or nonresponders to conventional CRT.
No takes yet. Share an insight, caveat, or question.
Elliott et al. (2021) studied Heart failure requiring cardiac resynchronization therapy. Leadless pacemaker and subcutaneous implantable cardioverter-defibrillator (S-ICD) positioning was evaluated. Leadless cardiac resynchronization therapy using the WiSE-CRT system improves symptoms and left ventricular remodeling in patients who are untreatable or nonresponders to conventional CRT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: